Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Spasmodic torticollis Stories

2011-02-02 07:11:00

GREENSBORO, N.C., Feb. 2, 2011 /PRNewswire/ -- In support of the focal dystonia community, Merz Pharmaceuticals today announced the launch of a new educational website, FocalDystoniaExchange.com, where people affected by certain focal dystonias, as well as caregivers, family and friends, can learn more about the conditions and access helpful resources. For people who suffer from focal dystonias (movement disorders characterized by muscle contractions and spasms that cause twisting and...

2011-01-18 14:59:52

Michele Tagliati, M.D., new director of Cedars-Sinai's Movement Disorders Program, says certain disabilities "remain remarkably stable" long-term in treated patients Parkinson's disease symptoms begin subtly and worsen as damage to certain brain cells continues. But an electrical stimulation device implanted deep in the brain and programmed remotely, along with medications, may provide some control of "motor symptoms" common to the disease, such as shaking, stiffness, and loss of muscle...

2010-12-02 21:34:47

Botulinum toxin A creates muscle weakness and atrophy following long term use A new study by researchers at the Faculty of Kinesiology, University of Calgary, is raising questions about the therapeutic use of botulinum toxin A. The study found that animals injected with Clostridium Botulinum type A neurotoxin complex (BOTOX, Allergan, Inc., Toronto, Ontario, Canada) experienced muscle weakness in muscles throughout the body, even though they were far removed from the injection site. The study...

2010-11-05 07:11:00

GREENSBORO, N.C., Nov. 5, 2010 /PRNewswire/ -- Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash. The U.S. Food and Drug Administration (FDA) approved XEOMIN on July 30, 2010, for the treatment of...

2010-10-05 07:11:00

GREENSBORO, N.C., Oct. 5 /PRNewswire/ -- Merz Pharmaceuticals today announced that Xeomin® (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010. XEOMIN is a botulinum toxin type A that is free from accessory proteins. It is FDA-approved for the treatment of adults with...

2010-08-02 07:11:00

GREENSBORO, N.C., Aug. 2 /PRNewswire/ -- Merz Pharmaceuticals today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin® (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people...

2010-04-21 07:00:00

PHOENIX, April 21 /PRNewswire/ -- One of the world's most fashionable beauty treatments is gaining popularity for something other than the war on wrinkles. Botulinum Toxin, commonly known as Botox, is being used at the Muhammad Ali Parkinson Center at Barrow Neurological Institute to help manage symptoms associated with Parkinson's disease and other movement disorders. "Botox is the most powerful nerve toxin known to man and it's dramatically improving the quality of life for people with...

2010-04-13 07:11:00

GREENSBORO, N.C., April 13 /PRNewswire/ -- Merz Pharmaceuticals announces that results from several new studies examining Xeomin® (incobotulinumtoxinA), a botulinum neurotoxin type A (free from complexing proteins), also referred to as NT 201, will be presented today at the 62nd American Academy of Neurology (AAN) annual meeting in Toronto, Canada. Results of studies exploring the safety and efficacy of Xeomin® in the treatment of focal dystonias...

2009-06-19 09:50:00

WASHINGTON, June 19 /PRNewswire/ -- The Center for Laser Surgery, Washington, DC has announced the availability of Dysport, abobotulinum toxin-A. Dysport, recently FDA approved, is the first cosmetic neurotoxin available alongside the widely used BOTOX(R) Cosmetic (botulinum toxin-A). The Center for Laser Surgery was principal investigator of the FDA Stage III Clinical Trials for Dysport. As Washington, DC, Maryland and Virginia's largest and most experienced Botox practice, the center was...

2009-06-09 06:00:00

-Second Data Set Presented at MDS- PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented at the Movement Disorder Society (MDS) 13th Annual International Congress in Paris, France. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA)...